Free Trial

Matt Hewitt Analyst Performance

Analyst at Craig Hallum

Matt Hewitt is a stock analyst at Craig Hallum focused in the medical sector, covering 7 publicly traded companies. Over the past year, Matt Hewitt has issued 2 stock ratings, including and buy recommendations. While full access to Matt Hewitt's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matt Hewitt's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 7 Years
Buy Recommendations
61.54% 8 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy61.5%8 ratings
Hold38.5%5 ratings
Sell0.0%0 ratings

Out of 13 total stock ratings issued by Matt Hewitt at Craig Hallum, the majority (61.5%) have been Buy recommendations, followed by 38.5% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
85.7% of companies on NASDAQ
6 companies
NYSE
14.3% of companies on NYSE
1 company

Matt Hewitt, an analyst at Craig Hallum, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
85.7%
Computer and Technology
1 company
14.3%

Matt Hewitt of Craig Hallum specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
3 companies
42.9%
COMP - SOFTWARE
1 company
14.3%
MEDICAL SERVICES
1 company
14.3%
MEDICAL INFO SYS
1 company
14.3%
ELECTROMEDICAL EQUIPMENT
1 company
14.3%

Matt Hewitt's Ratings History at Craig Hallum

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3/25/2026Lower Price Target$0.71$5.00Buy
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
6/13/2025Lower Price Target$19.25$36.00Buy